Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy
AJ Marian, E Braunwald - Circulation research, 2017 - Am Heart Assoc
Hypertrophic cardiomyopathy (HCM) is a genetic disorder that is characterized by left
ventricular hypertrophy unexplained by secondary causes and a nondilated left ventricle …
ventricular hypertrophy unexplained by secondary causes and a nondilated left ventricle …
MicroRNAs in cardiac diseases
RMW Colpaert, M Calore - Cells, 2019 - mdpi.com
Since their discovery 20 years ago, microRNAs have been related to posttranscriptional
regulation of gene expression in major cardiac physiological and pathological processes …
regulation of gene expression in major cardiac physiological and pathological processes …
Transient receptor potential channels in cardiac health and disease
T Hof, S Chaigne, A Récalde, L Salle, F Brette… - Nature Reviews …, 2019 - nature.com
Transient receptor potential (TRP) channels are nonselective cationic channels that are
generally Ca2+ permeable and have a heterogeneous expression in the heart. In the …
generally Ca2+ permeable and have a heterogeneous expression in the heart. In the …
[HTML][HTML] Hypertrophic cardiomyopathy: genetics and clinical perspectives
CM Wolf - Cardiovascular diagnosis and therapy, 2019 - ncbi.nlm.nih.gov
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease and
defined by unexplained isolated progressive myocardial hypertrophy, systolic and diastolic …
defined by unexplained isolated progressive myocardial hypertrophy, systolic and diastolic …
[HTML][HTML] Forensic transcriptome analysis using massively parallel sequencing
C Haas, J Neubauer, AP Salzmann, E Hanson… - Forensic Science …, 2021 - Elsevier
The application of transcriptome analyses in forensic genetics has experienced tremendous
growth and development in the past decade. The earliest studies and main applications …
growth and development in the past decade. The earliest studies and main applications …
miR-30c and miR-181a synergistically modulate p53–p21 pathway in diabetes induced cardiac hypertrophy
SK Raut, GB Singh, B Rastogi, UN Saikia… - Molecular and cellular …, 2016 - Springer
Abstract p53–p21 pathway mediates cardiomyocyte hypertrophy and apoptosis and is
upregulated in diabetic cardiomyopathy (DbCM). We investigated role of microRNAs in …
upregulated in diabetic cardiomyopathy (DbCM). We investigated role of microRNAs in …
A systematic review of microRNAs in patients with hypertrophic cardiomyopathy
FL Scolari, LS Faganello, HI Garbin, BP e Mattos… - International journal of …, 2021 - Elsevier
Abstract Background Several microRNAs (miRNA) have been associated with hypertrophic
cardiomyopathy (HCM), but studies differ regarding methods employed. In an attempt to …
cardiomyopathy (HCM), but studies differ regarding methods employed. In an attempt to …
Peripheral blood miRNAs as a biomarker for chronic cardiovascular diseases
Y Jiang, H Wang, Y Li, S Guo, L Zhang, J Cai - Scientific reports, 2014 - nature.com
Vascular diseases are the most prevalent diseases worldwide. This study intended to
analyze peripheral blood miRNA levels and their correlation with NT-pro-BNP and cTN-I in …
analyze peripheral blood miRNA levels and their correlation with NT-pro-BNP and cTN-I in …
MicroRNAs in hypertrophic, arrhythmogenic and dilated cardiomyopathy
E Chiti, M Di Paolo, E Turillazzi, A Rocchi - Diagnostics, 2021 - mdpi.com
MicroRNAs (miRNAs) are a class of non-coding RNAs of about 20 nucleotides in length,
involved in the regulation of many biochemical pathways in the human body. The level of …
involved in the regulation of many biochemical pathways in the human body. The level of …